Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- On World AIDS Day, threat to access to medicines looms large
- Delhi HC sets aside Centre’s decision to ban 344 fixed dose combination drugs
- RCEP must not be another TPP, say 316 regional civil society groups
- TPP Inquiry: Government majority backs a dead horse but Labor and Greens slam TPP
- Is the govt mulling a surgical strike on medicines?